Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Cyclerion Therapeutics Inc

CYCN
Current price
3.25 USD +0.21 USD (+6.91%)
Last closed 2.95 USD
ISIN US23255M1053
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 7 663 219 USD
Yield for 12 month +5.52 %
1Y
3Y
5Y
10Y
15Y
CYCN
21.11.2021 - 28.11.2021

Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a systemic sGC stimulator for the treatment of rare kidney disease. It has a license agreement with Akebia to develop, manufacture, medical affair, and commercializes Praliciguat and other related products. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts. Address: 245 First Street, Riverview II, Cambridge, MA, United States, 02142

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

4.00 USD

P/E ratio

Dividend Yield

Current Year

+2 000 000 USD

Last Year

Current Quarter

+1 806 000 USD

Last Quarter

+194 000 USD

Current Year

+2 000 000 USD

Last Year

Current Quarter

+1 806 000 USD

Last Quarter

+194 000 USD

Key Figures CYCN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -9 582 000 USD
Operating Margin TTM 27.80 %
Price to Earnings
Return On Assets TTM -19.76 %
PEG Ratio
Return On Equity TTM -30.36 %
Wall Street Target Price 4.00 USD
Revenue TTM 2 000 000 USD
Book Value 3.48 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 14.10 %
Dividend Yield
Gross Profit TTM 2 000 000 USD
Earnings per share -1.25 USD
Diluted Eps TTM -1.25 USD
Most Recent Quarter IV 2024
Quarterly Earnings Growth YOY
Profit Margin -152.85 %

Dividend Analytics CYCN

Max Ratio

>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Dividend History CYCN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
Dividend CAGR 3Y
Dividend CAGR 5Y
Dividend CAGR 10Y
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
Forward Annual Dividend – USD
Last Split Factor 1:20
Payout Ratio TTM
Last Split Date 16.05.2023

Stock Valuation CYCN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 2.22
Price Sales TTM 3.83
Enterprise Value EBITDA 0.56
Price Book MRQ 0.87

Financials CYCN

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators CYCN

For 52 weeks

1.27 USD 9.47 USD
50 Day MA 2.69 USD
Shares Short Prior Month 70 843
200 Day MA 2.90 USD
Short Ratio 1.18
Shares Short 41 890
Short Percent 2.48 %